Review finds newer antiseizure drugs generally spare cognition
Cognitive Side Effects of Antiseizure Medications in Adults with Epilepsy: An Update with a Focus on New Therapeutic Agents.
AI Summary
This narrative review asked how antiseizure medications affect cognition in adults with epilepsy, with particular attention to newer drugs introduced since 2009. The authors searched PubMed for research published through December 2025, drawing on randomised trials, observational studies, meta-analyses, and systematic reviews. The main outcomes were effects on attention, processing speed, memory, language, and executive function. The abstract reports no single quantitative estimate of cognitive risk, reflecting the varied evidence across medications, doses, treatment combinations, and individual patients.
Overall, newer antiseizure medications—including cannabidiol (CBD), lacosamide, brivaracetam, and others—showed generally favourable cognitive profiles at recommended doses, especially when used alone or in carefully selected combinations. Eslicarbazepine and cenobamate may produce mild, dose-related cognitive effects at the upper end of their recommended ranges, while topiramate and zonisamide remain more consistently associated with cognitive problems. Older adults and people with intellectual disabilities may be especially vulnerable. Because this is a narrative review rather than a new clinical trial, the abstract-based summary cannot establish that one medication is universally superior or fully separate medication effects from epilepsy-related cognitive impairment; no quantitative results are provided in the abstract.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.